These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16053341)

  • 21. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Osteoporosis therapy. Bisphosphonates compared].
    MMW Fortschr Med; 2003 Mar; 145(13):60. PubMed ID: 15101545
    [No Abstract]   [Full Text] [Related]  

  • 23. [Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
    Trémollières F
    Gynecol Obstet Fertil; 2001 Nov; 29(11):846-52. PubMed ID: 11770280
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
    Reginster JY; Malaise O; Neuprez A; Jouret VE; Close P
    Drugs Aging; 2007; 24(5):351-9. PubMed ID: 17503893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of intravenous bisphosphonates in osteoporosis.
    Civitelli R; Napoli N; Armamento-Villareal R
    Curr Osteoporos Rep; 2007 Mar; 5(1):8-13. PubMed ID: 17320022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
    Ettinger MP; Gallagher R; MacCosbe PE
    Endocr Pract; 2006; 12(5):522-8. PubMed ID: 17002926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates: new indications and methods of administration.
    Reid IR
    Curr Opin Rheumatol; 2003 Jul; 15(4):458-63. PubMed ID: 12819475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastroenterologists and choosing the right bisphosphonate.
    Leder BZ; Kronenberg HM
    Gastroenterology; 2000 Sep; 119(3):866-9. PubMed ID: 10982780
    [No Abstract]   [Full Text] [Related]  

  • 33. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
    Sartori L; Adami S; Filipponi P; Crepaldi G
    Aging Clin Exp Res; 2003 Aug; 15(4):271-83. PubMed ID: 14661816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
    Curković B
    Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
    Kherani RB; Papaioannou A; Adachi JD
    Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
    Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.